Frontier Medicines

For many disease-causing proteins, there are no known classical binding sites, so there’s been no way to develop small-molecule drugs to intervene. Frontier uses quan­ti­ta­tive proteomics and machine learning to find pockets where small molecules can bind covalently, opening up formerly undruggable targets such as KRAS, a molecular switch driving many forms of cancer.